Royal Bank of Canada
BIVI icon

Royal Bank of Canada’s BioVie BIVI Stock Holding History

Royal Bank of Canada’s Portfolio BIVI Stock Details BIVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
205
-1,995
-91% -$2.56K ﹤0.01% 7124
2025
Q4 		$2K Buy
2,200
+1,200
+120% +$1.93K ﹤0.01% 6888
2025
Q3 		$2K Sell
1,000
-50
-5% -$203 ﹤0.01% 6863
2025
Q2 		$10K Sell
1,050
-78
-7% -$771 ﹤0.01% 6471
2025
Q1 		$11K Buy
1,128
+278
+33% +$4.44K ﹤0.01% 6117
2024
Q4 		$17K Buy
+850
New +$20.5K ﹤0.01% 6166
2024
Q2 		– Sell
-81
Closed -$4K – 7054
2024
Q1 		$4K Sell
81
-31
-28% -$3.18K ﹤0.01% 6484
2023
Q4 		$14K Buy
112
+106
+1,767% +$31.8K ﹤0.01% 6413
2023
Q3 		$2K Sell
6
-124
-95% -$48.5K ﹤0.01% 6768
2023
Q2 		$56K Buy
130
+125
+2,500% +$84.2K ﹤0.01% 5718
2023
Q1 		$4K Hold
5
– – ﹤0.01% 6611
2022
Q4 		$4K Buy
5
+4
+400% +$2.16K ﹤0.01% 6774
2022
Q3 		$0 Buy
+1
New +$238 ﹤0.01% 7443
2022
Q2 		– Hold
0
– – – 7372
2022
Q1 		– Sell
-235
Closed -$106K – 7728
2021
Q4 		$106K Buy
+235
New +$136K ﹤0.01% 5885

Other funds holding BIVI

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.7% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Royal Bank of Canada's BIVI Position: Q1 2026 in Review

Royal Bank of Canada reduced its BioVie (BIVI) stake by 91% in Q1 2026, selling an estimated $2.56K and leaving 205 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7124.

Royal Bank of Canada first reported a position in BIVI in Q4 2021 and has held it in 14 quarters since. The position peaked at $106K in Q4 2021. 33 funds tracked by Wall St. Rank hold BIVI as of Q1 2026.

  • Royal Bank of Canada held 205 shares of BioVie worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 1,995 BioVie shares in Q1 2026, an estimated $2.56K.
  • BioVie made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7124 holding.
  • Royal Bank of Canada first reported a position in BioVie in Q4 2021 and has held it in 14 quarters since.
  • Royal Bank of Canada's BioVie position peaked at $106K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held BioVie as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.